Press release
Hepatocellular Carcinoma Drugs Market Opportunity Analysis, 2018-2026
Hepatocellular carcinoma (HCC) is a major type of primary liver cancer that arises from the liver cells or hepatocytes. The disease is found to occur mainly in patients with hepatitis B, hepatitis C, cirrhosis, obesity, and diabetes. Diagnosis of hepatocellular carcinoma is mainly done by imaging tests such as ultrasound, MRI, CT scan, and liver biopsy. Treatment for hepatocellular carcinoma mainly includes radiation therapy, ablation therapy in addition to chemotherapy and targeted drug therapy. A majority of the HCC patients are diagnosed at the end-stage of liver dysfunction. Due to poor prognosis of the condition, mortality rate is approximately the same as the incidence rate. Therefore, early detection of the cancer is an important parameter to improve the survival of affected patients, thus aiding in growth of the global hepatocellular carcinoma drugs market.Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1596
Market Dynamics
Increasing incidence of global hepatocellular carcinoma cases is a major factor augmenting market growth. According to the research by International Journal of Cancer Research and Treatment, 2014, HCC is the sixth most common type of cancer worldwide and third most common cause of death worldwide, fifth for men and eighth for women. The disease accounts for more than 5% of all cancers and for 80-90% of primary liver cancers. Also, according to the Addis Ababa University, 2017, hepatocellular carcinoma (HCC) accounted to 854,000 new cases of liver cancer and 810,000 related deaths in 2015. Furthermore, increasing incidence and mortality of hepatocellular carcinoma is attributed to the emergence of new risk factors such as hepatitis B and C viral infections, metabolic disorders such as diabetes and non-alcoholic fatty liver disease, and exposure to toxins such as alcohol and aflatoxin.
Moreover, clinical advancements integrated with the approval of novel drugs by the regulatory agencies for treating hepatocellular carcinoma is augmenting growth of the market. For instance, in April 2017, the U.S. Food & Drug Administration expanded the indications of regorafenib (Stivarga) manufactured by Bayer HealthCare Pharmaceuticals Inc., for treatment of patients with hepatocellular carcinoma. The therapy showed significant improvement in survival for patients after the failure of standard treatments. Also, in 2017, the U.S. FDA granted accelerated approval for nivolumab (Opdivo) drug developed by Bristol-Myers Squibb for the treatment of hepatocellular carcinoma.
However, the side effects associated with the drugs such as anemia, constipation, low white blood cell count, pneumonia are the factors restraining growth of the market.
Regional Dynamics
Regional segmentation of the global hepatocellular carcinoma drugs market by Coherent Market Insights comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global hepatocellular carcinoma drugs market over the forecast period, owing to increasing prevalence of the disease and the rising number of clinical trials undertaken by the manufacturers to address the unmet medical needs of the patients. According to the survey by the Health Science Department, University of California, Los Angeles, (UCLA), 2017, hepatocellular carcinoma (HCC) accounts for three quarters of liver cancers in the U.S. with an estimated 40,000 Americans diagnosed with liver cancer in 2017 and more than 28,000 deaths are reported from the disease. Also, in April 2018, Eli Lilly and Company completed Phase 3 research study of Cyramza (ramucirumab) as a single agent in the second-line treatment of people with hepatocellular carcinoma, also known as liver cancer.
Asia Pacific is expected to gain significant traction in the global hepatocellular carcinoma drugs market owing to rising number of research and development activities undertaken by the manufacturers in the region to develop effective therapies. For instance, in February 2017, Daiichi Sankyo, a pharmaceutical company in Japan completed the Phase-3 study of tivantinib indicated for patients with hepatocellular carcinoma treated with other therapies.
Access Table of Content (TOC) Of the Report @ https://www.coherentmarketinsights.com/ongoing-insight/toc/1596
Competitive Analysis
The manufactures are focused on strategic collaborations to jointly develop and commercialize immunotherapies indicated to treat broad range of tumors. For instance, in 2014, Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd. signed a strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination therapies with Opdivo, to help address the unmet medical needs of patients with cancer in Japan, South Korea and Taiwan. Also, in 2015, Novartis Pharmaceuticals initiated the Phase 2 trials to compare the safety and efficacy for dovitinib and sorafenib in adult patients with advanced hepatocellular carcinoma.
Key players operating in the global hepatocellular carcinoma drugs market include Novartis Pharmaceuticals, Bayer AG, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson, Celgen Corporation, Amgen Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., and Takeda Pharmaceutical Co. Lt
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
1001 4th Ave, #3200Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hepatocellular Carcinoma Drugs Market Opportunity Analysis, 2018-2026 here
News-ID: 1171381 • Views: …
More Releases from Coherent Market Insights
![Bacterial Sialadenitis Market to Witness Significant Growth in the Upcoming Years | Novartis AG, Sanofi S.A., Johnson & Johnson, Abbott Laboratories](https://cdn.open-pr.com/L/9/L906130289_g.jpg)
Bacterial Sialadenitis Market to Witness Significant Growth in the Upcoming Year …
The global bacterial sialadenitis market size is projected to reach US$ 664.4 million by 2030, from US$ 467.8 million in 2023, growing at a CAGR of 5.1% during the forecast period.
The latest market intelligence report published by CMI with the title "Global Bacterial Sialadenitis Market 2024, Growth Opportunities, and Forecast" provides actionable insights on Pharmaceutical industry. The report provides demand analysis, industry insights, competitive intelligence, and customer database.
The Research report…
![Absorbent Glass Mat Battery Market Growth to US$ 14.72 Billion: Trends Analysis and Share Forecast by 2031 | EnerSys, Exide Technologies, GS Yuasa](https://cdn.open-pr.com/L/9/L906953725_g.jpg)
Absorbent Glass Mat Battery Market Growth to US$ 14.72 Billion: Trends Analysis …
The latest market intelligence report published by CMI with the title "Global Absorbent Glass Mat Battery Market Market 2024, Growth Opportunities, and Forecast" provides actionable insights on Energy industry. The report provides demand analysis, industry insights, competitive intelligence, and customer database.
The Research report on Absorbent Glass Mat Battery Market Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y…
![Global Single Shaft Turbine Market Value Expected to Hit $3.78 Billion: Share and Trends Analysis Through 2031 | Siemens, GE, Voith, ANDRITZ, Toshiba](https://cdn.open-pr.com/L/9/L906973861_g.jpg)
Global Single Shaft Turbine Market Value Expected to Hit $3.78 Billion: Share an …
The latest market intelligence report published by CMI with the title "Global Single Shaft Turbine Market Market 2024, Growth Opportunities, and Forecast" provides actionable insights on Energy industry. The report provides demand analysis, industry insights, competitive intelligence, and customer database.
The Research report on Single Shaft Turbine Market Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate,…
![Major Player in the Myasthenia Gravis Treatment Market Size, Trends, and Forecast to 2031 |Novartis AG, Takeda Pharmaceutical Company Limited, Grifols, S.A](https://cdn.open-pr.com/L/9/L906524756_g.jpg)
Major Player in the Myasthenia Gravis Treatment Market Size, Trends, and Forecas …
The latest market intelligence report published by CMI with the title "Global Myasthenia Gravis Treatment Market 2024, Growth Opportunities, and Forecast" provides actionable insights on Pharmaceutical industry. The report provides demand analysis, industry insights, competitive intelligence, and customer database.
The Research report on Myasthenia Gravis Treatment Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing…
More Releases for Pharmaceutical
Mevastatin Market Is Booming Worldwide |Zhejiang Hisun Pharmaceutical, Guangdong …
Global Mevastatin Market Size research report 2022 offers in-depth assessment of revenue growth, market definition, segmentation, industry potential, influential trends for understanding the future outlook and current prospects for the market. This study provides information about the sales and revenue during the historic and forecasted period of (2022 to 2028). Understanding the segments helps in identifying the importance of different factors that aid market growth. Estimations about the CAGR value for…
Global Specialty Pharmaceutical Market Driving Future Growth on Specialty Pharma …
Global Specialty Pharmaceutical Industry Synopsis:
The Specialty Pharmaceutical Market report provides a detailed analysis of this business space. The market is analyzed in terms of production as well as consumption. Based on the production aspect, the report includes particulars pertaining to the manufacturing processes of the product, alongside revenue and gross margins of the respective manufacturers.
The Global Specialty Pharmaceutical Market will reach xxx Million USD in 2020 with CAGR xx%…
Metronidazole Market by Top Manufacturers – Hongyuan Pharmaceutical, Yinhe Aar …
Metronidazole is an antibiotic and antiprotozoal medication, with the chemical formula C6H9N3O3 of can be used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis, and bacterial vaginosis among others. Metronidazole is white crystalline powder, which can also be called as Fragyl Orvagil, Trichazol, Metronid, etc.
Get Sample Copy of this Report @ https://www.bigmarketresearch.com/request-sample/2724380?utm_source=Anil&utm_medium=OPR
Scope of the Report:
This report focuses on the Metronidazole in global market, especially in…
Metronidazole Market by Top Manufacturers – Hongyuan Pharmaceutical, Yinhe Aar …
Metronidazole is an antibiotic and antiprotozoal medication, with the chemical formula C6H9N3O3 of can be used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis, and bacterial vaginosis among others. Metronidazole is white crystalline powder, which can also be called as Fragyl Orvagil, Trichazol, Metronid, etc.
Get Sample Copy of this Report @ https://www.bigmarketresearch.com/request-sample/2724380?utm_source=Anil&utm_medium=OPR
Scope of the Report:
This report focuses on the Metronidazole in global market, especially in…
Metronidazole Market to 2023 (+5% CAGR Expected) Top Player Profiles – Hongyua …
Metronidazole is an antibiotic and antiprotozoal medication, with the chemical formula C6H9N3O3 of can be used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis, and bacterial vaginosis among others. Metronidazole is white crystalline powder, which can also be called as Fragyl Orvagil, Trichazol, Metronid, etc.
Get Sample Copy of this Report @ https://www.bigmarketresearch.com/request-sample/2724380?utm_source=Anil&utm_medium=OPR
Scope of the Report:
This report focuses on the Metronidazole in global market, especially in…
Metronidazole Market by Top Key Participant Hongyuan Pharmaceutical, Yinhe Aarti …
Metronidazole is an antibiotic and antiprotozoal medication, with the chemical formula C6H9N3O3 of can be used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis, and bacterial vaginosis among others. Metronidazole is white crystalline powder, which can also be called as Fragyl Orvagil, Trichazol, Metronid, etc.
Get Sample Copy of this Report @ https://www.researchbeam.com/global-metronidazole-2018-by-manufacturers-regions-type-and-application-forecast-to-2023-market/request-sample?utm_source=Anil
Scope of the Report:
This report focuses on the Metronidazole in global market, especially in North…